Ballesteros, PA, García-Carbonero, I, Gonzalez, EE, Marin, AP, Lorente, D, de Liaño, AG, Ortega, EM, Colomo, LJ, Puente, J, Gonzalez, I, Calvo, OF, Palacios, GA, Mendizabal, I, Navarro, EP, Domínguez, JID, Esteban-Villarrubia, J, Billalabeitia, EG, Oria, GAD. Defining molecular correlates of response using spatial transcriptomics in the SOGUG-AUREA trial. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3696. PMID:. IF:65.400(Q1/1D).

España, MAG, Calle, SG, Flores, EG, Sosa, MM, Tocino, RV, Plazas, JG, Monteagudo, RF, Aguilera, MJS, Herrero, MDRM, Gargia, TG, Zafra, GM, Arévalo, MA, Orozco, EJ, Manrique, ACV, Alfonso, PG, Montes, AF, Ninerola, RQ, de Castro, EM, Verdaguer, H, García, RV. Characterization of locally advanced rectal cancer (LARC) patients (pt) in Spanish TTD-RETUD registry. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1362. PMID:. IF:65.400(Q1/1D).

Kuboki, Y, Pietrantonio, F, Salvatore, L, Meriggi, FA, Modest, DP, Yaeger, R, Ruiz, E, Taieb, J, Karamouzis, MV, Esaki, T, Kim, TW, Cremolini, C, Strickler, JH, Masuishi, T, Paez, D, Chan, E, Chao, J, Tran, Q, Fakih, M, Hong, DS. Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1317. PMID:. IF:65.400(Q1/1D).

Ahrens, M, Haanen, JBAG, Albiges, L, Goupil, MG, Boleti, E, Gravis, G, Flechon, A, Grimm, MO, Bedke, J, Barthelemy, P, Gauna, DEC, Gonzalez, BM, Ivanyi, P, Rottey, S, Floercken, A, Rodriguez, CS, Rey, JPM, Burkholder, I, Hartmann, A, Bergmann, L. Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first-line treatment. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3211. PMID:. IF:65.400(Q1/1D).

Sanborn, RE, Zhou, CC, Tang, KJ, Cho, BC, Cheng, S, Popat, S, Ono, A, Lu, S, Majem, M, Aguilar, A, Campelo, MDG, Hayashi, H, Lee, KY, Lee, SH, Delmonte, A, Alatorre-Alexander, J, Richardson, G, Santos, V, Dooms, C, Sabari, JK, Shu, CA, Girard, N, Mansfield, AS, Park, K, Xia, YC, Bhattacharya, A, Buyukkaramikli, N, Perualila, N, Diels, J, Acharya, S, Chandler, C, Proskorovsky, I, Dearden, L, Wortman-Vayn, H, Mahadevia, PJ, Knoblauch, RE, Agrawal, T, Baig, M, Felip, E. Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study. Targeted Oncology. 2025; 20(6)DOI:10.1007/s11523-025-01182-0. PMID:41184595. IF:4.000(Q2/3D).

Cardozo, AR, Kesselheim, A, Tibau, A. Magnitude of clinical benefit demonstrated in trials supporting FDA and EMA Approval of drugs for hematological malignancies, 2020-2024. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1886. PMID:. IF:65.400(Q1/1D).

Muñoz-Couselo, E, Berciano-Guerrero, MA, Crespo, G, Castaño, AG, Manzano, JL, Miguel, PAD, Rosa, CA, Cerezuela-Fuentes, P, Puértolas, T, Sanz, LG, Medina, J, Cunquero-Tomás, A, Majem, M, Fernández, LA, Espinosa, E, Bellido, L, Soria, A, Bujosa, A, Algarra, SM, Marquez-Rodas, I. Real-world outcomes after immunotherapy discontinuation in advanced melanoma: Insights from the GEM1801 study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2263. PMID:. IF:65.400(Q1/1D).

Bergmann, L, Albiges, L, Ahrens, M, Goupil, MG, Boleti, E, Gravis, G, Flechon, A, Grimm, MO, Bedke, J, Barthelemy, P, Gauna, DEC, Gonzalez, BM, Ivanyi, P, Floercken, A, Rodriguez, CS, Rey, JPM, Gruenwald, V, Burkholder, I, Hartmann, A, Haanen, JBAG. Relevance of the CPS score and tumor nephrectomy in the SUNNIFORECAST trial comparing ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3216. PMID:. IF:65.400(Q1/1D).

Chen, TWW, Giani, C, Ljevar, S, Reinhorn, D, Denu, R, Bhadri, VA, Jaeger, R, Ibrahim, T, D'Ambrosio, L, Bae, S, Han, I, Garcia, AS, Abreu, MH, Ribeiro, MFSA, Mariuk-Jarema, A, Yang, V, Sbaraglia, M, Antonescu, C, Baldi, GG, Stacchiotti, S. International multicenter retrospective study of spindle cell/ sclerosing rhabdomyosarcoma (S-RMS): A PUSH platform study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3306. PMID:. IF:65.400(Q1/1D).

Cerna, JGY, Mirallas, O, Garces, VN, Puerto, DAG, Velilla, G, Pastor, PG, Puga, TG, Salgado, MAV, Martínez, A, Gonzalez, AH, Sorolla, MA, Di Muzio, A, González, M, Martinez-Garcia, MJ, Villacampa, G, Balana, C, Galceran, JC, Dienstmann, R, Sanchez, JMS, Vieito, M. Molecular landscape of IDH1/2-mutant gliomas: A Spanish multicentric cohort. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1270. PMID:. IF:65.400(Q1/1D).

Muñiz, NH, Strauss, S, Redondo, A, Palmerini, E, Gaffaro, GJM, Chamberlain, FE, Martinez, V, Ibrahim, T, Trufero, JM, Morales, CMV, Billalabeitia, EG, Lleida, RT, Jiménez, CL, Mukherjee, U, Wan, S, Ramos, R, Garcia, AMG, Moura, DD, Martin-Broto, J. Phase II of sunitinib plus nivolumab in advanced alveolar soft-part sarcoma results from the GEIS, ISG and UCL IMMUNOSARC II study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3296. PMID:. IF:65.400(Q1/1D).

Hwang, T, Kesselheim, A, Tibau, A. Magnitude of clinical benefit of cancer medicines in curative setting and health technology assessment decisions in Europe. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2893. PMID:. IF:65.400(Q1/1D).

Cardozo, AR, Tibau, A, Liu, I, Han, J, Cliff, E, Kesselheim, A. Assessing outcomes emerging after confirmatory trials of accelerated approval drugs, 1992-2021. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2894. PMID:. IF:65.400(Q1/1D).

Lopez, JS, Besora, CP, Malaret, M, Joaquín, AB, Recio, SM, Momblan, AM, Dalmau, GM, Majem, M. Evaluation of a non-pharmacological skin care intervention for the prevention and treatment of skin toxicities induced by immunotherapy in oncology patients. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3451. PMID:. IF:65.400(Q1/1D).

Blay, JY, Lleida, RT, Martin-Broto, J, Caetano, C, De Haan, JJ, Debruyne, C, Desar, I, Duffaud, F, Gelderblom, H, Gennigens, C, Italiano, A, Colomo, LJ, Lapeire, L, Mazzeo, F, Philip, J, Striefler, JK, Svobodova, M, Tala, I, Morales, CMV, Stacchiotti, S. Navigating regulatory complexity in combined studies under clinical trial and in vitro diagnostic regulations: Lessons from the CHONQUER study on molecular prescreening for IDH1 mutation in chondrosarcoma. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3359. PMID:. IF:65.400(Q1/1D).

Martin-Broto, J, Ospina, GM, Garcia, AS, Trufero, JM, Martinez-Garcia, J, Fidalgo, JAP, Morales, CMV, Jurado, JC, Ledesma, P, Grifman, M, Moura, DD, Muñiz, NH. CIRTUSARC: A multicenter, open-label phase II trial of cirtuvivint as second-line therapy in selected advanced soft-tissue sarcomas. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3354. PMID:. IF:65.400(Q1/1D).

Stacchiotti, S, Yonemori, K, Beato, CM, Campos, FAB, Conley, AP, Debruyne, C, Endo, M, Hiraga, H, Kichenadasse, G, Laptewicz, M, Lleida, RT, Morais, ANR, Yoshihiro, N, Pereira, C, Salawu, AT, Takenaka, S, Tanaka, K, Tinoco, G, Vianna, KM, Bovée, JVMG. Isocitrate dehydrogenase 1 (IDH1) mutation testing in the phase III study of ivosidenib vs placebo in IDH1-mutant conventional chondrosarcoma (CHONQUER). ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3355. PMID:. IF:65.400(Q1/1D).

Molasiotis, A, Jordan, K, Karthaus, M, Dranitsaris, G, Roeland, EJ, Schwartzberg, LS, Bonizzoni, E, Vazquez, EB, Buchler, T, Cheng, Y, Christoph, DCC, Alfonso, PG, Lu, X, Majem, M, Mavroudis, D, Syrigos, K, Tomlins, E, Zhou, Z, Zimovjanova, M, Aapro, MS. Personalizing antiemetic prophylaxis for patients at high emetic risk: Results from the MyRisk Trial. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3413. PMID:. IF:65.400(Q1/1D).

Bernabé, R, De Castro, J, Collado, R, Escudero, V, Gutiérrez, F, Arranz, S, Gordo, R, Arroyo, I, Majem, M. Economic Burden of Disease Management and Recurrences After Complete Resection of Early-Stage ALK plus Non-Small Cell Lung Cancer (NSCLC) in Spain. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Johnson, ML, Arriola, E, Kato, T, Girard, N, Gadgeel, S, Tarruella, MM, Newsom-Davis, T, Polaczek, M, Chen, X, Stefaniak, K, Lowery, C, Angra, N, Doherty, G, Ahn, MJ. Phase 3 eVOLVE-Lung02 Trial of Volrustomig plus Chemotherapy (CT) vs Pembrolizumab plus CT in Metastatic NSCLC With PD-L1 TC <50%. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).